VYNE Therapeutics News

Buy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical Data

TipRanksMay 6 10:15 ET

VYNE Therapeutics Says US FDA Clears Its Investigational New Drug Application for Potential Autoimmune Treatment

VYNE Therapeutics (VYNE) said Monday the US Food and Drug Administration has cleared its Investigational New Drug Application for VYN202, its potential autoimmune disease treatment Vyne said it plans

MT NewswiresMay 6 08:51 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersMonogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. Allarity Therapeutics (NASDAQ:ALLR) s

BenzingaMay 6 08:06 ET

Express News | VYNE Therapeutics Announces FDA Clearance Of IND Application For VYN202

BenzingaMay 6 08:04 ET

Express News | Vyne Therapeutics Inc - Plans to Initiate Phase 1B Trials, With Top Line Results Anticipated in Second Half of 2025

ReutersMay 6 08:02 ET

Express News | Vyne Therapeutics Inc - Phase 1a Sad/Mad Trial Expected to Start This Quarter

ReutersMay 6 08:02 ET

Express News | Vyne Therapeutics Announces FDA Clearance of Ind Application for Vyn202, a Novel Bd2-Selective Bet Inhibitor

ReutersMay 6 08:00 ET

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligoBRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc.

GlobeNewswireMay 1 08:00 ET

VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans

Yahoo FinanceApr 13 08:08 ET

12 Health Care Stocks Moving In Friday's After-Market Session

GainersQilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their outstanding shares is at $37.1 million. Sunshine Biopharma (NASDAQ:SB

BenzingaMar 29 16:30 ET

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing proprietary, i

GlobeNewswireMar 19 08:00 ET

VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Yahoo FinanceMar 3 07:03 ET

Vyne Therapeutics Inc's New Natural and Human Disruptions Risk – A Cause for Worry?

TipRanksMar 3 01:01 ET

Vyne Therapeutics Files for $250M Mixed Shelf

Seeking AlphaMar 1 17:40 ET

Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments

TipRanksFeb 29 15:25 ET

Express News | HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target

Moomoo 24/7Feb 29 15:06 ET

VYNE Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/29/2024 166.19% HC Wainwright & Co. → $5.75 Reiterates Buy → Buy 10/30/2023 166.19% HC Wainwright & Co.

BenzingaFeb 29 15:04 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)

TipRanksFeb 29 11:01 ET

Recap: VYNE Therapeutics Q4 Earnings

VYNE Therapeutics (NASDAQ:VYNE) reported its Q4 earnings results on Thursday, February 29, 2024 at 08:00 AM.Here's what investors need to know about the announcement.EarningsVYNE Therapeutics beat est

BenzingaFeb 29 08:30 ET

Express News | VYNE Therapeutics Ended 2023 With $93.3M Of Cash, Cash Equivalents, Restricted Cash And Marketable Securities, Providing Runway Through The End Of 2025

Moomoo 24/7Feb 29 08:12 ET